Kornimate/medical-research-clean huggingface dataset:
vertebroplasty using real-time, fluoroscopy-controlled, catheter-assisted, low-viscosity cement injection

Conditions: Osteoporosis; Compression Fracture

Summary: th low viscosity cement injection is safe in vertebroplasty procedure with comparacle out come in pain relief.

pain relief; comparatle cement leakage; comparacle irradiation dose：less

Eligibility criteria:
inclusion criteria: * all painful fracture that can not be relieved by pain killer. exclusion criteria: * infection and malignancy in local region
effect of whitening agent with emulsion gel in saliva and halitosis

Conditions: Xerostomia; Halitosis

Summary: the objective of this study is to evaluate how well the study product, crest daily whitening serum, alleviates xerostomia and perceived halitosis over 1 week of use.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * can produce an unstimulated salivary flow rate of 0.18ml/min. or less. * score of 3 or more on question 1 of the vas dry mouth scale (how severe is your dryness right now?), evaluated in the pre-product use dry mouth \& sensitivity questionnaire. * evidence of currently taking a stable dose (3 months or more) of xerostomia-inducing medication such as, antihypertensives, anti-anxiety agents, psychiatric remedies, antihistamines and etc. • at screening, participants may present the prescription bottle, a picture of the prescriptions bottle or medical records showing the prescription. * subject not currently using any teeth whitening or desensitizing products that contain potassium nitrate such as sensodyne, pronamel etc. * subject willing to comply with the study regimen and products. * not consume alcohol for 24 hours prior to their visit. * not brush their teeth for 1.5 hours prior to their visit. * not have had anything to eat or drink (including chewing gum or eating candy) for 1.5 hours prior to their visit). water is acceptable to drink up to 1 hour prior to the study visit. * not smoke 1.5 hours prior to their visit exclusion criteria: i. subjects who are currently pregnant (self-reported). ii. unstimulated salivary flow rate of more than 0.18ml/min iii. subjects that have ever received therapeutic radiation in the head and neck area. iv. subjects with a diagnosis of conditions that would affect salivary flow such as sjogren's syndrome per the investigator's expert opinion. v. subjects with a condition the investigator believes not suitable for the study, such as autoimmune diseases and radiation therapy to head and neck region that impact salivary flow. vi. subjects that currently use whitening toothpaste, desensitizing toothpaste, or any other products causing similar results. vii. subjects currently participating in any other research studies. viii. subject unable to provide consent (e.g. cognitively impaired adults). ix. non-english speaking
urine nt-probnp levels and echocardiographic findings in very low birth weight (vlbw) infants

Conditions: Infant, Premature; Ductus Arteriosus, Patent; Ventricular Function, Left

Summary: the aim of the study is to evaluate urine nt-probnp levels and new echocardiographic findings in vlbw infants. the investigators hypothesize that high urine nt-probnp concentrations are associated with a hemodynamically significant ductus arteriosus. the investigators also hypothesized that new echocardiographic parameters such as isovolumic relaxation time (ivrt)is useful for the prediction of ductus intervention.

urine samples were collected within 24 to 48 hours of age, on day 7, on day 14 and on day 28 of life. the samples were spun and the platelet-free urine was stored at -80°c until nt-probnp analysis. the nt-probnp assay was performed with an automated immunoassay (roche diagnostics). color doppler and tissue doppler echocardiography was determined at the same time as the urine collection. new echo parameters such as ivrt, tissue velocity, strain and strain rate were measured and compared with the standard parameters for significant ductus arteriosus. furthermore we compared the tissue doppler measurements with clinical findings.

Eligibility criteria:
inclusion criteria: * written parental informed consent * vlbw infants * admitted to our nicu within 48 hours after birth exclusion criteria: * no written parental informed consent * congenital heart disease * death

Keywords: nt-probnp
use of rds multisense® in post-icu patients in the covid-19 era

Conditions: Post ICU Rehabilitation

Summary: in this clinical study, the investigators will compare vital parameters measurements obtained using continuous data from reference monitors and continuous wireless multisense® monitoring patch in 60 post-icu (intensive care unit) patients and over 7 days.

the multisense® strip is a unique, band aid-sized, clinical signal quality, connected strip for real-time monitoring of cardio-respiratory parameters. the multisense® strip measures in real-time, remotely and continuously 11 clinical key-indicators by being attached to the patient thorax: ecg trace, heart rate, oxygen saturation (spo2), respiratory rate and relative respiration depth, pulse transit time, plethysmographic trace, perfusion index, skin temperature, physical activity and body position. designed to be worn continuously for at least seven days, the patient can keep the patch during his sleep or in the shower. the aim of this study is to determine the quality of measurements of clinical signs provided by multisense® strip in comparison to measurements made with conventional medical devices in the hospital setting, in terms of accuracy, connectivity, generation of artifactual data and stability of data transmission. the study population includes 60 patients transferred to post-icu units for a minimum of 5 days. once in the post-icu unit, the multisense® strip will be attached on patient's thorax. the monitoring will last between 5 to 7 days.

Eligibility criteria:
inclusion criteria: * man or woman over 18 years old. * patient previously cared in an icu for severe covid-19 pneumonia, covid-related condition or similar neurological compromise necessitating post-icu rehabilitation * negative respiratory sars-cov-2 (severe acute respiratory syndrome-corona virus-2) samples * patient admitted in a post-icu rehabilitation unit with an expected length of stay \> 5 days * patient able to receive and understand information related to the study and give written informed consent. or if the patient is not capable, presence of a next of kin able to receive and understand information related to the study and give written informed consent for the patient * patient authorizing the treatment of their personal data collected during the study (box checked in the consent form) * patient affiliated to the french social security system. exclusion criteria: * patient with a skin disease that would preclude the use of an adhesive. * patient with an implantable device such as a pacemaker * pregnant or lactating patient. * patient in exclusion period (determined by a previous or a current study). * patient under guardianship or trusteeship. * patient under the protection of justice.

Keywords: vital signs connected device real-time monitoring post-icu cardio-respiratory monitoring
influence of spinal deformity on tha

Conditions: THA

Summary: the aim of the study is to understand the effect of spinal deformity and altered sagittal plane parameters of lumbosacral complex on acetabular cup position in tha.

investigators will find out if there is change in the acetabular cup including the abduction and anteversion angles in patients who had tha and has spinal deformity

Eligibility criteria:
inclusion criteria: * all patients who had primary tha in 6 month duration * patients from 30 to 70 years old with primary tha exclusion criteria: * patients who have ankylosing spondylitis * patients with revised tha * patients with associated injuries in lower limb
a study of rituximab (mabthera) in combination with chemotherapy in participants with cd20-positive b-cell chronic lymphocytic leukemia

Conditions: Lymphocytic Leukemia, Chronic

Summary: this observational study will evaluate the safety and efficacy of rituximab in combination with chemotherapy in first- and second-line treatment of participants with cluster of differentiation 20 (cd20)-positive b-cell chronic lymphocytic leukemia. data will be collected from eligible participants receiving rituximab according to the summary of product characteristics (spc) during 6 months of treatment.


Eligibility criteria:
inclusion criteria: - participants with cd20-positive b-cell chronic lymphocytic leukemia eligible for first-line or second-line therapy according to the approved spc exclusion criteria: - contraindications to rituximab therapy according to the approved spc
value of capnography during nurse administered propofol sedation (naps)

Conditions: Hypoxia

Summary: propofol is widely used by anaesthesiologists for deep sedation and general anaesthesia. during recent years nurses trained in the use of low dose propofol sedation (naps) during endoscopy have been introduced. the method has been implemented at the endoscopic unit at gentofte hospital since 2008(1). propofol has a respiratory depressive effect which may result in depressed oxygen saturation in the blood (hypoxia). due to a short acting half life this is prevented in the majority of cases. however, in spite of this, hypoxia is experienced in 4,4% of patients receiving propofol during endoscopy at gentofte hospital (unpublished data). it is well known that hypoxia constitutes a late expression of reduced oxygen tension in peripheral tissues. whether the addition of capnography to standard monitoring during naps may be of benefit is widely unknown. the aim of this study is to examine whether the additional use of capnography to standard monitoring during endoscopy may improve patient safety in patients undergoing low dose propofol sedation by reducing the number, duration and level of hypoxic events. the trial is a randomized clinical prospective case-control study.


Eligibility criteria:
inclusion criteria: * aged 18 or above * compliant with the criteria of naps. exclusion criteria: * no signed written consent obtained * american society of anaesthesiologists (asa) physical status classification \> 3 * sleep apnoea * allergy against soy, eggs and peanuts * body mass index (bmi) \> 35 kg/m2 * mallampati score ≥ 4 * acute gastrointestinal bleeding * subileus * ventricular retention * severe cold ((30% ≤ fev1 \<50%) * failed data collection

Keywords: naps hypoxia propofol capnography endoscopy sedation
genetic determinants of the metabolism of non-nucleoside reverse transcriptase inhibitors

Conditions: HIV Infections

Summary: to see if certain variations in the cyp2b6 gene contribute to differences in plasma drug levels and central nervous system side affects in people who take nevirapine or efavirenz.


Eligibility criteria:
inclusion criteria: * healthy african american men and women. * 18-55 years of age. * willing and able to provide written informed consent. exclusion criteria: * currently or recently (within the previous 30 days) received medications known or likely to be metabolized by, or interact wth the cyp450 enzymes. * prior or current hepatic or psychiatric disease illness that in the judgment of the investigator would interfere in the study performance. * active alcohol or illicit drug abuse use that in the judgment of the investigator would interfere in the study performance. * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \>1.5 x upper limit of normal. * positive pregnancy test in women of childbearing potential.

Keywords: nevirapine efavirenz pharmacokinetics healthy cyp2b6 hiv/aids
modified constrained - induced movement therapy compared to intensive bimanual training

Conditions: Stroke

Summary: the purpose of the study is to evaluate the benefit of two different treatment approaches for the hemiplegic arm, modified constraint-induced movement therapy and task-related bimanual training.

detailed description: constrained-induced movement therapy seems to be an efficacious treatment approach for a certain subgroup of patients with moderate to mild hemiparesis after stroke. still it remains unclear whether the training intensity or restriction of the better arm plays the bigger role. cimt or mcimt is usually compared to standard care of lower intensity with no constraint of the better arm, or other treatments that do not focus on functional (task-specific) training for the hemiplegic arm. bimanual training, implying training of activities requiring use of both arms, may however, be even more effective than mcimt, provided that the training is of similar intensity. the purposes of this study are: 1. to compare the functional effect of mcimt to bimanual training of equal intensity in order to examine if one of the treatment approaches is superior to the other regarding the regaining of motor abilities. 2. based on fmri scans of a subgroup of patients, to examine whether cortical reorganization after stroke differs depending on the type of treatment received (mcimt vs bimanual training). 3. to examine the rationale for implementing new treatment approaches in primary- and secondary health care, and thereby contribute to improved coordination between specialist and municipal health care systems. patients in both groups will participate in a 4 week training program, either mcimt or bimanual. in both groups cognitive techniques will be used to increase adherence. the patients will be examined when screening, before and after the intervention, and 3 months after completed intervention.

Eligibility criteria:
inclusion criteria: * upper extremity hemiparesis * between 2 and 16 weeks post-stroke * at least 10º active extension of the wrist and at least 10º active extension of the thumb and at least 2 additional fingers exclusion criteria: * cognitive problems, mini mental status \< 24 * excessive pain in the paretic extremity * major medical problems

Keywords: stroke arm paresis mcimt bimanual training rehabilitation
the effect of light level applied during breastfeeding on maternal stress, anxiety, psychological well-being and breastfeeding motivation

Conditions: Stress; Anxiety

Summary: to determine the effect of the light level applied during breastfeeding on the mother's stress, anxiety, psychological well-being and breastfeeding motivation. this research was planned as a single-blind randomized controlled experimental type study comparing separate groups as intervention-placebo controlled. data will be collected with the introductory information form, psychological well-being scale, perceived stress scale (asö/psö-14), state-trait anxiety inventory (stai) and breastfeeding motivation scale (for primiparous mothers). the effect of two different light levels on mothers will be examined.


Eligibility criteria:
inclusion criteria: * being 18 years of age or older, volunteering. exclusion criteria: * having any problem that prevents communication
discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity

Conditions: Rheumatoid Arthritis

Summary: patients and physicians often differ in their perceptions of rheumatoid arthritis (ra) disease activity, as quantified by the patient's global assessment (pga) and by the evaluator's global assessment (ega). the objectives of this study were: 1. to explore the extent and reasons for the discordance between patients and physicians in their perception of ra disease activity 2. to determine if this discordance at baseline is associated with ra outcomes at 1 year (remission, function and structure) in early arthritis (ea) in daily clinical practice. * patients: from the french cohort of early arthritis (ea) espoir³ (at least 2 swollen joints for less than 6 months, dmard naïve), fulfilling the acr-eular criteria for ra at baseline analysis: at baseline, agreement between pga and ega (bland-altman plot) was assessed. multivariate linear regression was used to determine the patient and ea features independently associated with discordance (calculated as pga - ega). logistic regression was used to analyze discordance as│pga - ega│≥20. multivariate logistic models were used to determine if discordance at baseline is associated with remissions (boolean, sdai and das28), functional stability (haq≤0.5 and deltahaq≤0.25) and absence of radiographic progression (delta sharp score\<1) after 1 year of follow-up.


Eligibility criteria:
inclusion criteria: * fulfilling the acr-eular criteria for ra exclusion criteria: * no ra
a non-interventional study on xarelto for treatment of venous thromboembolism (vte) and prevention of recurrent vte in patients with active cancer

Conditions: Venous Thrombosis and Pulmonary Embolism

Summary: this study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for vte (venous thromboembolism).


Eligibility criteria:
inclusion criteria: * adult female and male patients with active cancer other than fully treated basal-cell or squamous-cell carcinoma of the skin (active cancer defined as the diagnosis or treatment of cancer in the previous \< 6 months or recurrent or metastatic cancer) * patients that have been treated with standard of care anticoagulation (low molecular weight heparin / vitamin k antagonist) for treatment of dvt and/ or pe (index vte event) and/ or prevention of recurrent dvt and pe for at least 4 weeks prior to inclusion in the study * patients for whom the decision was made to start rivaroxaban for treatment of dvt and/ or pe and/ or prevention of recurrent dvt and pe * patients with eastern cooperative oncology group (ecog) performance status score of 0, 1 or 2 * patients who are willing to participate in this study (signed informed consent) * patients who are available for follow-up with a life expectancy \>6 months exclusion criteria: * the contra-indications according to the local marketing authorization must be considered * patients who developed an index vte event despite chronic anticoagulant therapy * patients receiving apixaban, edoxaban or dabigatran or any investigational drug as the initial therapy for the index vte event * patients participating in an investigational program with interventions outside of routine clinical practice with exception of oncology investigational trials

Keywords: cancer deep venous thrombosis pulmonary embolism
clinical study to assess the long-term safety and tolerability of act 064992 in patients with symptomatic pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the main objective of the ac 055 303/seraphin ol study, which will follow the ac 055 302/seraphin study, will be to assess the long-term safety and tolerability of act 064992 in patients with symptomatic pah.


Eligibility criteria:
inclusion criteria: * signed informed consent prior to initiation of any study-mandated procedure. * patients with pulmonary arterial hypertension and having completed the event-driven study, ac 055 302/seraphin, or patients who have experienced a clinical worsening of pah in ac 055 302/seraphin and for whom a written approval to roll over into this study has been obtained from the sponsor. * women of childbearing potential must have a negative pre-treatment serum pregnancy test and must use a reliable method of contraception during study treatment and for at least 28 days after study treatment termination. exclusion criteria: * any major violation of protocol ac 055 302/seraphin. * pregnancy or breast-feeding. * ast and/or alt \> 3 times the upper limit of the normal range. * any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease. * known hypersensitivity to act 064992 or any of the excipients.

Keywords: seraphin pulmonary arterial hypertension act-064992
carbon ion radiotherapy in treating patients undergoing systemic therapy for oligo-metastatic prostate cancer

Conditions: Metastatic Prostate Carcinoma

Summary: the goal of this clinical study is to determine impact of carbon ion radiotherapy (cirt) treatment in combination with systemic therapy for oligo-metastatic prostate cancer. the primary objective: to determine disease biochemical progression-free survival in man with oligo-metastatic (m1a/b) prostate cancer undergoing systemic therapy with definitive radiotherapy of the primary tumor. the secondary objective: to determine local control, overall survival and quality of life in men with oligo-metastatic prostate cancer undergoing carbon ion radiotherapy


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed adenocarcinoma of the prostate 2. age ≥ 20 and \< 80 years of age 3. ecog ps 0 or 1 4. life-expectancy ≥1 year 5. stage t1-4,n0-1,m1a/b disease on imaging, with a combined maximum of 3 synchronous lesions. 6. ability to understand and willingness to sign informed consent exclusion criteria: 1. no pathologically confirmed adenocarcinoma of the prostate 2. visceral metastasis 3. previous pelvic radiotherapy or prostatectomy 4. severe systemic disorders
activities to change your mood: a test of the acceptability and initial efficacy in clinical samples and healthy controls

Conditions: Schizophrenia Disorders

Summary: this is a study investigating how brief online activities can influence mood and attitudes.


Eligibility criteria:
inclusion criteria: * aged 18-65 * schizophrenia group - have a psychotic disorder diagnosis * healthy control group - do not have a current dsm-5 diagnosis via the scid-5
post-market registry of stroke patients treated with medtronic neuro thrombectomy devices to collect real world data in south east asia

Conditions: Stroke, Acute

Summary: the purpose of this post-market registry is to collect real-world data associated with the use of medtronic market-released neurothrombectomy devices in acute ischemic stroke (ais) patients from countries in south east asia.

this is a prospective, multi-center, non-randomized, observational registry designed to collect real world data associated with the use of medtronic market-released neurothrombectomy devices in acute ischemic stroke (ais) patients from countries in south east asia, including singapore, thailand and vietnam. the primary objective of this registry is to assess clinical outcomes associated with the use of these devices in patients experiencing ais due to large intracranial vessel occlusion within 8 hours of symptom onset. this registry may enroll up to 500 patients. this clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (that is, clinical trial information for this applicable clinical trial was submitted under section 402 (j)(4)(a) of the public health service act and 42 cfr 11.60 and is not subject to the deadlines established by sections 402 (j)(2) and (3) of the public health service act or 42 cfr 11.24 and 11.44.)

Eligibility criteria:
inclusion criteria: 1. subject/subject's legally authorized representative has given informed consent according to country regulations, and/or ec requirements. 2. subject has experienced an acute ischemic stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ica), m1 and m2 segments of the middle cerebral artery (mca), basilar, and vertebral arteries. 3. subject has been or will be treated with a medtronic market-released neurothrombectomy device as the initial device used to remove the thrombus. 4. subject is willing to participate in a 90-day follow-up visit. 5. treatment within 8 hours of stroke symptom onset (defined as stroke onset to access puncture). exclusion criteria: 1. concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm or where the study procedure or treatment might confound the study analysis.